ObsEva SA OTC Markets

OBSEF

CH1260041939

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:23:36 2024-05-10 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		-99.98%	-100.00%

Apr. 03	ObsEva to Delist from the SIX Swiss Exchange	MT
Mar. 20	ObsEva SA Announces to Wind-Down the Operations	CI

Press Release : ObsEva Provides Update on -2-

January 11, 2021 at 01:00 am EST

   CEO Office contact / Investor contact 
 
   Shauna Dillon 
 
   https://www.globenewswire.com/Tracker?data=4IJeHBbH1yXoEeDsIVUZW44DKIuQ4J_3q7xyqRVTvDZUj0nVXpZbZcrq8ywXC5i2lcw-lI0MqH21qBwXlVKjJkZhgv1hvOQ6QiT1mtRVC37jABni5nHSREL1H69Dz7SR 
Shauna.dillon@obseva.ch 
 
   +41 22 552 1550 
 
 
 
 
 
 
 
 
 
 
 
   Attachment 
 
 
   -- Update on Yselty (Linzagolix) Clinical Development Program_11 Jan 2021 
      https://ml-eu.globenewswire.com/Resource/Download/3d434cf2-b8ea-426a-95c8-5bec36b0f316

(END) Dow Jones Newswires

January 11, 2021 01:00 ET (06:00 GMT)

Latest news about ObsEva SA

ObsEva to Delist from the SIX Swiss Exchange	Apr. 03	MT
ObsEva SA Announces to Wind-Down the Operations	Mar. 19	CI
ObsEva SA Announces Catarina Edfjäll to Step Down from the Board	Mar. 19	CI
ObsEva to Wind Down, Flags SIX Swiss Delisting	Feb. 28	MT
ObsEva Secures Temporary Moratorium Against Creditors	Jan. 31	MT
ObsEva to File for Moratorium in Geneva, Switzerland	Nov. 30	MT
ObsEva to Return Global Rights on Ebopiprant to Xoma	23-10-30	MT
ObsEva Net Loss Narrows in H1	23-09-27	MT
ObsEva SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-26	CI
ObsEva Terminates Licensing Deal with Yuyuan BioScience for Oral Oxytocin Receptor	23-07-13	MT
ObsEva SA Announces Termination of Its Sub-Licensing Agreement with Yuyuan Bioscience	23-07-13	CI
SIX Group Makes Index Adjustments Following Review	23-07-11	MT
Switzerland's ObsEva Appoints Permanent CEO	23-05-02	MT
ObsEva SA announced that it expects to receive CHF 1.54 million in funding from ObsEva USA Inc.	22-12-07	CI

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat womenâs reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and uterine fibroids; Nolasiban (OBE001), an oral oxytocin receptor antagonist, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	108B
REGENERON PHARMACEUTICALS, INC.	+10.87%	104B
ARGENX SE	+1.28%	22.33B
BIONTECH SE	-13.14%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-38.36%	17.74B
BEIGENE, LTD.	-10.66%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	14.05B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.51B

Bio Therapeutic Drugs

ObsEva SA OTC Markets

Equities

OBSEF

CH1260041939

Biotechnology & Medical Research

Press Release : ObsEva Provides Update on -2-

Latest news about ObsEva SA

Chart ObsEva SA

Company Profile

Income Statement Evolution

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs